BRIEF-Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.